University Patent Licensing Agreement: Clauses That Matter

A university patent licensing agreement is the document that decides whether a spinout owns a business or rents one. Founders read it for the fees. Buyers, investors and sublicensees read it for everything else, because the clauses that settle what the licence is worth three years later are mostly not the payment lines. The fee stack is real and it deserves its own analysis, which is why we wrote a separate breakdown of university patent licensing fees. This page covers the rest: the definitions, the grant, what the university keeps, diligence, sublicensing and change of control. Where possible it quotes the wording universities actually publish, so you can hold your own draft up against it. ## What a university patent licensing agreement actually transfers Not the patent. A university or research institution rarely sells its intellectual property outright; it grants a licence that lets a company make, use or sell the technology under specific conditions while the institution keeps title. That one fact explains most of the agreement. Because the university stays the owner, every right you receive is a carve-out from its ownership, every obligation you accept protects its ability to take the rights back, and every transaction you later do with the technology runs through a contract you signed when you had the least leverage. If you want the full picture of how a university patent licensing deal is structured from disclosure to signature, start there. Many spinouts sign an option before the full licence, and what a university license option agreement gives founders is a separate question. Here we stay inside the licence itself. ## The map: twelve sections in a standard agreement Formats vary, but most university licences follow the same order: recitals, definitions, grant of rights, sublicensing, consideration, diligence, reporting and audit, patent prosecution and maintenance, representations and warranties, indemnification and insurance, term and termination, and boilerplate. Consideration has its own article. Indemnification and boilerplate are rarely where deals are won or lost. The sections below are the ones that change the value of the asset. ## Definitions: where the agreement is really decided Lawyers say the definitions are the agreement. In a university licence that is literally true, because royalty obligations, scope and termination all key off a handful of defined terms. ### Licensed Product and Valid Claim Harvard's published sample exclusive licence defines a Licensed Product, country by country, as anything whose making, use or sale would infringe at least one pending Valid Claim (were it to have issued) or issued Valid Claim in that country. A Valid Claim, in turn, includes a pending claim that has been asserted and continues to be prosecuted in good faith. Read that carefully. Royalties can attach to a product covered only by claims that have not been granted and may never be. That is a normal and defensible structure, since the licensee is buying a position in a pending application. But it means the royalty base and the legal protection are not the same thing. We hold ourselves to the same honesty on our own portfolio: a pending application is a pending application, not a granted patent, and any valuation that blurs the two is wrong. Two practical consequences. First, the definition is country by country, so a product sold where no claim exists owes nothing there. Second, once a claim is finally rejected or abandoned it drops out, and with it the royalty in that country. Track it. ### Net Sales The royalty is a percentage of Net Sales, so the deductions list matters more than the rate. The Harvard sample allows customary discounts actually taken, returns, customer freight and separately stated sales taxes, and nothing else. Transfers to affiliates are valued at arm's length, and non-cash consideration at fair market value. If your business model involves bundling, subscriptions or hardware sold near cost, this is the clause to model, and royalty rates by industry only make sense once the base is pinned down. ### Sublicense, defined wider than you think This is the definition founders most often miss. The Harvard sample defines a Sublicense to include not only any grant of rights under the patents, but also any option or right to negotiate for such a grant, and any standstill obligation not to grant rights to a third party, regardless of what the document is called. In plain terms: an option you give a strategic partner, or an exclusivity promise in a term sheet, can be a sublicence under your university agreement. That triggers the sublicence approval terms, the copy delivery obligation and, in many agreements, the university's share of sublicence income. Ask the question before you sign the partnership, not after. ## The grant: exclusivity, field and territory The operative clause in the Harvard sample grants an exclusive, royalty-bearing licence to develop, make, have made, sell, import and distribute Licensed Products, solely for use within the Field and, where specified, the Territory. Three dimensions stack independently. Exclusivity runs from exclusive, through sole (one commercial licensee but the university keeps its own right to practise), to non-exclusive. Field limits the application. Territory limits the geography. An agreement can be exclusive in one field and territory and non-exclusive everywhere else. Field is where the money hides. AUTM's practitioner guide gives the example of a compound useful against several central nervous system diseases, licensed only for therapeutics for Alzheimer's disease, and advises defining the field carefully and attaching diligence to each part of it. A narrow field keeps the price down today and caps the exit value tomorrow. A broad field costs more diligence. Pick the field your business plan genuinely needs in its first five years, and negotiate a right of first negotiation on adjacent fields rather than paying for all of them now. Expect resistance to broad grants. A policy paper signed by Stanford, Harvard, MIT, the University of California and others warns that a licence covering all fields for the life of the patent can have negative consequences if the technology turns out to have unanticipated uses the licensee cannot develop. That document shapes how US offices draft, so it is worth reading as a map of what the other side believes. ## What the university keeps ### Reserved research rights Even an exclusive licence is not fully exclusive. The Harvard sample reserves the right, for Harvard and for other not-for-profit research organisations, to practise the patents solely for research, educational and scholarly purposes. The same policy paper goes further and recommends reserving these rights in all fields, including research sponsored by commercial entities, plus the right to transfer materials to other non-profits. For most licensees this is harmless. It becomes material in two cases: when your competitors are themselves non-profits or government labs, and when industry-sponsored research at the university starts to look like a competing development programme. Ask for the reserved rights to exclude commercially sponsored work in your field. ### Federal government rights and march-in If federal money funded the research, the US government keeps a licence and certain powers, and the Harvard sample says any right granted beyond what Bayh-Dole permits will be modified to conform. The power that worries investors is march-in. Under the statute, the funding agency can require an exclusive licensee to grant licences to others, or grant them itself, where the licensee has not taken effective steps to achieve practical application, where health or safety needs are unmet, where federal public use requirements are unmet, or where the US manufacturing obligation is breached. Whatever its track record, investors price the possibility. A diligence review will check whether the invention is federally funded and whether you are commercialising it. ### The US manufacturing preference This one catches European licensees. For a federally funded invention, the university cannot grant anyone the exclusive right to use or sell it in the United States unless they agree that products will be manufactured substantially in the United States, a requirement the funding agency can waive on a showing that domestic manufacture is not commercially feasible or that US manufacturers could not be found. If your production is in Germany or Asia and your licence is exclusive for the US, get the waiver path into the plan before signature. It is a statute, not a negotiable clause. ## Diligence: the clause that ends licences Fees cost money. Diligence costs the licence. The Harvard sample requires commercially reasonable efforts to develop products according to a development plan, introduce them to market and sell them, plus hard development milestones on fixed dates. An annual report is due within 60 days of year end, with enough detail for the university to judge compliance. The cure procedure is the part to read twice. If you expect to miss a milestone, you notify in advance with an explanation and a plan. If the explanation is lack of money, it fails: the sample states in terms that lack of finances will not constitute reasonable basis for missing a milestone. Miss the deadline after the short cure window and it is a material breach with an immediate termination right. The policy paper explains the intent: objective, time-limited milestones, with termination or conversion to non-exclusive as the penalty, and possibly a requirement to sublicense into markets the licensee is not serving. The Harvard sample builds this in through a defined Third Party Proposed Product, an application the university believes you are not actively developing. So write milestones you can hit in a bad funding year. Tie them to technical events you control, not to raising capital, and negotiate a paid extension mechanism instead of relying on discretion. ## Sublicensing: the clause your future partner reads first Most spinouts commercialise through partners, so the sublicence clause is the one a pharma company, OEM or acquirer reads before anything else. The Harvard sample permits sublicensing on written terms that are subordinate to the main agreement and must include: flow-down of the university's indemnity, automatic termination with the main licence, a ban on further sublicensing, limits on assignment, a rule that the head licence prevails, and delivery of every executed sublicence and its royalty reports to the university. Two of those matter commercially. Termination with the head licence means your partner's rights die with yours, so serious partners will ask for survival or direct licence rights if you default. And the no further sublicensing rule can block a partner who needs to bring in a manufacturer or distributor. Negotiate both up front. The revenue share on sublicence income is covered in the fees article. ## Change of control and assignment The Harvard sample defines Change of Control as a merger, a majority acquisition of voting power, or a sale of substantially all relevant assets where the prior holders lose majority control, and expressly excludes raising working capital through private equity issuance. It flags the clause as negotiable. That exclusion protects your funding rounds. What it does not exclude is the exit. Wherever a licence restricts assignment or attaches consideration to a change of control, and the spinout's main asset is the licence, that clause sits directly on the asset being sold. Acquirers check it first, so negotiate it while you still have leverage: assignment to an acquirer of the whole business without consent, and any change of control payment fixed in the agreement rather than left open. ## How a buyer reads your licence We sit on the transaction side of patents, so here is the reading a buyer actually gives a university licence, in order. Is the scope real? Which claims are granted, which are pending, and in which countries. Is the field wide enough for the buyer's product, and can the licence be assigned to them? Are diligence milestones current or already in cure? Does any partnership qualify as a sublicence under that wide definition? Is the invention federally funded, and if so, where are products made? Every unclear answer becomes a discount or a condition. That is why we put assessment ahead of any buyer conversation: in our own work, physics-grade claim reconstruction, detectability analysis and validity probability are benchmarked at 0.76 percent mean absolute percentage error against real-world outcomes before a patent reaches a buyer. The point is not the tooling. It is that evidence on claim strength changes the negotiation. And if you hold the rights outright rather than under a licence, compare carefully whether to license or sell a patent at all. For sellers who choose to sell, our brokerage commission is paid on completion, minimum EUR 5,000, no sale no fee. This is general information, not legal advice; have a licensing attorney review any agreement before you sign it. ## FAQ Can a university terminate a patent licence if the startup runs out of money? Yes, if running out of money means missing a diligence milestone. The Harvard sample excludes lack of finances as a reasonable explanation for a missed milestone, and a miss after the cure window is a material breach with a right to terminate. Milestones tied to technical events, with a paid extension option, are the protection. Does an exclusive university licence stop the university using the invention? No. Universities almost always reserve the right to practise the invention for research and education, for themselves and for other non-profit institutions, and the leading US offices recommend reserving it in every field. You can usually negotiate limits on commercially sponsored research in your field. Do I have to manufacture in the United States under a university licence? Only if you take exclusive US rights to an invention made with federal funding. Then Bayh-Dole requires products to be manufactured substantially in the US unless the funding agency grants a waiver. Non-exclusive licences and inventions without federal funding are not caught. Is a licence on a pending patent application worth anything? It can be. Agreements like Harvard's treat pending claims prosecuted in good faith as Valid Claims, so a product can owe royalties before grant. But protection depends on grant, which is never certain, so price the licence on realistic claim scope, not on the application as filed.